Stockreport

Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation

NewAmsterdam Pharma Company N.V. - Ordinary Shares  (NAMS) 
PDF NewAmsterdam REMBRANDT clinical trial to leverage Caristo CaRi-Heart® and CaRi-PlaqueTM technologies for coronary inflammation and plaque measurements and monitoringSTAM [Read more]